EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today announced that it has signed a Memorandum of Understanding (“MOU”) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”) to establish a tri-party collaboration with next-generation therapies derived from induced pluripotent stem cells (“iPSC”). * The MOU details the parties intentions to collaborate on the development, manufacturing and commercialization of a first of its kind next generation of off-the-shelf oncology cell therapies for cancer treatment applications and wellness Alfred Lim, Chief Executive officer of EUDA commented: “This collaborative agreement represents a significant milestone for our company. The agreement aligns with our strategy to strengthen commercialization and distribution capabilities in innovative, science-backed wellness and non-invasive healthcare products and services. We anticipate the market will be robust for our next generation therapies as we demonstrate the effectiveness of our top of the line suite of product offerings. Our products represent a dramatic improvement over the current products available today. We intend to reach our goal of increasing value for shareholders as we successfully launch this product in the market”.